Journal article

Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer's Disease

Alexa Pichet Binette, Etienne Vachon-Presseau, John Morris, Randall Bateman, Tammie Benzinger, D Louis Collins, Judes Poirier, John CS Breitner, Sylvia Villeneuve



BACKGROUND: Major prevention trials for Alzheimer's disease (AD) are now focusing on multidomain lifestyle interventions. However, the exact combination of behavioral factors related to AD pathology remains unclear. In 2 cohorts of cognitively unimpaired individuals at risk of AD, we examined which combinations of personality traits, neuropsychiatric symptoms, and cognitive lifestyle (years of education or lifetime cognitive activity) related to the pathological hallmarks of AD, amyloid-β, and tau deposits. METHODS: A total of 115 older adults with a parental or multiple-sibling family history of sporadic AD (PREVENT-AD [PRe-symptomatic EValuation of Experimental or Novel Treatments for AD] ..

View full abstract


Awarded by DIAN - National Institute on Aging

Funding Acknowledgements

This work was supported by a Canada Research Chair, a Canadian Institutes of Health Research Foundation Grant, a Canada Fund for Innovation Grant, and an Alzheimer's Association Grant (to SV) and a joint Alzheimer Society of Canada and Fonds de recherche Sante Quebec fellowship (to APB). PREVENT-AD was launched in 2011 as a

3.5 million, 7-year publicprivate partnership using funds provided by McGill University, the Fonds de Recherche du Quebec-Sante, an unrestricted research grant from Pfizer Canada, the Levesque Foundation, the Douglas Hospital Research Centre and Foundation, the Government of Canada, and the Canada Fund for Innovation. Private sector contributions are facilitated by the Development Office of the McGill University Faculty of Medicine and by the Douglas Hospital Research Centre Foundation ( collection and sharing for this project was supported by DIAN (UF1AG032438) funded by the National Institute on Aging, the German Center for Neurodegenerative Diseases, Raul Carrea Institute for Neurological Research, partial support by the Research and Development Grants for Dementia from Japan Agency for Medical Research and Development, and the Korea Health Technology R&D Project through the Korea Health Industry Development Institute.